SSY Group Limited — Earnings Release 2015

Oct 16, 2015

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [251 x 53] intentionally omitted <==

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

ANNOUNCEMENT OF TURNOVER AND GROSS PROFIT INFORMATION FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2015

The Company announces the turnover and gross profit information, which has not been reviewed by its auditors, for the nine months ended 30 September 2015.

The board of directors (the “Board”) of SSY Group Limited (the “Company”) announces the financial information of turnover and gross profit of the Company and its subsidiaries (together, the “Group”) for the nine months ended 30 September 2015 based on its management accounts which have not been reviewed by the auditors.

Turnover of the Group, which has not been reviewed by the auditors, for the nine months ended 30 September 2015 increased by 1.33% as compared with the same period of 2014 to HK$1,542 million, with gross profit margin of 46.5% (for the nine months ended 30 September 2014: 50.2%). Among which, sales of intravenous infusion solution (including the subcontracting products) for the nine months ended 30 September 2015 was HK$1,415 million consisting of the followings:

• sales of non-PVC soft bag and upright soft bag infusion solution was HK$889 million, representing 62.8% of the sales of intravenous infusion solution and an increase of 6.0% as compared with sales for the same period of 2014;

• sales of PP plastic bottle infusion solution was HK$358 million, representing 25.3% of the sales of intravenous infusion solution and an decrease of 11.2% as compared with sales for the same period of 2014;

• sales of glass bottle infusion solution was HK$168 million, representing 11.9% of the sales of intravenous infusion solution and an increase of 3.7% as compared with sales for the same period of 2014.

— 1 —

The Group has discontinued the operation of Xi’an Lijun Pharmaceutical Co., Ltd (“Xi’an Lijun”) since 31 October 2014. Accordingly, the Group had no results from Xi’an Lijun for the nine months ended 30 September 2015. The results from Xi’an Lijun for the nine months ended 30 September 2014 had been classified as a discontinued operation and thus not included in the financial information of turnover and gross profit for the same period of 2014 as announced above.

Shareholders and potential investors of the Company are advised to exercise caution in dealing in the shares of the Company.

On behalf of the Board Chow Hing Yeung Company Secretary

Hong Kong, 16 October 2015

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.

— 2 —